The Global Alopecia Drugs Market is estimated to be USD 869.4 Mn in 2021 and is expected to reach USD 1462.35 Mn by 2026, growing at a CAGR of 10.96%.
The increasing research and development for novel drug treatment of alopecia are anticipated to drive the market during the forecast period.
By Alopecia Types, the market is classified as Alopecia Areata, Alopecia Totalis, Alopecia Universalis, Cicatricial Alopecia, Traction Alopecia, Tinea Capitis, Androgenetic Alopecia, Anagen Effluvium, and Others. Amongst all, the Alopecia Areata segment is estimated to hold the highest market share during the forecast period.
By Drugs, the market is classified as Vasodilators (Minoxidil), 5-Alpha Reductase Inhibitors (Finasteride), Corticosteroids, and Others. Amongst all, the Vasodilators (Minoxidil) segment is estimated to hold the highest market share during the forecast period.
By Route of Administration, the market is classified into Injectable, Oral, and Topical. Amongst all, Injectable segment is estimated to hold the highest market share during the forecast period.
By Gender, the market is classified as Men And Women. Amongst the two, Women segment is estimated to hold the highest market share during the forecast period.
By Sales Channel, the market is classified as Prescriptions and OTC. Amongst the two, Prescriptions segment is estimated to hold the highest market share during the forecast period.
By Geography, North America is projected to lead the market.
2. Baricitinib is First JAK-Inhibitor received FDA approval in Phase 3 Alopecia Areata (AA) Trial - 3 rd March 2021
Market Dynamics
The major factor contributing to the growth of the alopecia drug market is the rising awareness about alopecia owing to rising stress levels, sedentary lifestyle, hormonal changes, and hereditary conditions. Furthermore, the rise in pollution and the growing geriatric population have increased the cases of hair loss. In addition, the increasing prevalence of cancer, hypertension, depression, etc., leading to hair loss, has raised the demand for the alopecia drugs market. However, as alopecia is not a life-threatening condition and lacks proper approved treatment, various patients do not opt for the treatment, which has hindered the market.The increasing research and development for novel drug treatment of alopecia are anticipated to drive the market during the forecast period.
Market Segmentation
The Global Alopecia Drugs Market is segmented further based on Alopecia Types, Drugs, Route of Administration, Gender, Sales Channel, and Geography.By Alopecia Types, the market is classified as Alopecia Areata, Alopecia Totalis, Alopecia Universalis, Cicatricial Alopecia, Traction Alopecia, Tinea Capitis, Androgenetic Alopecia, Anagen Effluvium, and Others. Amongst all, the Alopecia Areata segment is estimated to hold the highest market share during the forecast period.
By Drugs, the market is classified as Vasodilators (Minoxidil), 5-Alpha Reductase Inhibitors (Finasteride), Corticosteroids, and Others. Amongst all, the Vasodilators (Minoxidil) segment is estimated to hold the highest market share during the forecast period.
By Route of Administration, the market is classified into Injectable, Oral, and Topical. Amongst all, Injectable segment is estimated to hold the highest market share during the forecast period.
By Gender, the market is classified as Men And Women. Amongst the two, Women segment is estimated to hold the highest market share during the forecast period.
By Sales Channel, the market is classified as Prescriptions and OTC. Amongst the two, Prescriptions segment is estimated to hold the highest market share during the forecast period.
By Geography, North America is projected to lead the market.
Recent Developments
1. Concert Pharmaceuticals received the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for the Company’s oral Janus kinase inhibitor, CTP-543, for the treatment of adult patients with moderate-to-severe alopecia areata. - 8th July 20202. Baricitinib is First JAK-Inhibitor received FDA approval in Phase 3 Alopecia Areata (AA) Trial - 3 rd March 2021
Company Profiles
Some of the companies covered in this report are Cipla, Sun Pharmaceutical, Ranbaxy, Aurobindo, Accord Healthcare, Taisho Pharmaceutical, etc.Competitive Quadrant
The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.Why buy this report?
- The report offers a comprehensive evaluation of the Global Alopecia Drugs Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
- The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
- The report includes an in-depth market analysis using Porter’s 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
- The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
- The report also contains the competitive analysis using Positioning Quadrants, the analyst’s Proprietary competitive positioning tool.
Report Highlights:
- A complete analysis of the market, including parent industry
- Important market dynamics and trends
- Market segmentation
- Historical, current, and projected size of the market based on value and volume
- Market shares and strategies of key players
- Recommendations to companies for strengthening their foothold in the market
Frequently Asked Questions about the Global Alopecia Drugs Market
What is the estimated value of the Global Alopecia Drugs Market?
What is the growth rate of the Global Alopecia Drugs Market?
What is the forecasted size of the Global Alopecia Drugs Market?
Who are the key companies in the Global Alopecia Drugs Market?
Report Attribute | Details |
---|---|
No. of Pages | 192 |
Published | June 2021 |
Forecast Period | 2021 - 2026 |
Estimated Market Value ( USD
| USD 869.4 Million |
Forecasted Market Value ( USD
| USD 1462.35 Million |
Compound Annual Growth Rate | 11.0% |
Regions Covered | Global |
No. of Companies Mentioned | 21 |
Table of Contents
1 Report Description
2 Research Methodology
3 Executive Summary
4 Market Influencers
5 Market Analysis
6 Global Alopecia Drugs Market, By Alopecia Types
7 Global Alopecia Drugs Market, By Drugs
8 Global Alopecia Drugs Market, By Route of Administration
9 Global Alopecia Drugs Market, By Gender
10 Global Alopecia Drugs Market, By Sales Channel
11 Global Alopecia Drugs Market, By Geography
12 Competitive Landscape
13 Company Profiles
14 Appendix
Companies Mentioned
- Cipla
- Sun Pharmaceutical
- Micro Labs
- Torrent Pharma
- Indiabulls Pharmaceutical
- Johnson & Johnson
- Merck
- Kirkland Signature
- Histogen
- GlaxoSmithKline
- L`Oreal
- Concert Pharmaceuticals
- Aurobindo
- Accord Healthcare
- Ranbaxy
- Taisho Pharmaceutical
- Theradome
- Intas Pharmaceuticals
- Abbott
- Avacor
- Glenmark